Press Releases

Tris Pharma, Inc. a fully integrated, innovation-driven CNS company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit/Hyperactivity Disorder, and a pipeline of treatments for pain, addiction, spasticity and narcolepsy, today announced that it has acquired rights to TRN-261 a non-opioid drug candidate that Tris intends to develop for multiple indications within acute and chronic pain. TRN-261 has been extensively studied, and a large amount of sa

Millstone Medical Outsourcing  the industry’s leading partner of choice for medical manufacturers’ post-manufacturing and aftermarket services, announces its completed acquisition of Ethide Laboratories on November 14, 2022.Headquartered in West Warwick, Rhode Island, Ethide Labs has more than 60 years of experience in regulatory testing services for the medical device and pharmaceutical industries. Ethide Labs is an ISO 13485:2016 certified testing laboratory with capabiliti

Ocuphire Pharma, Inc. a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for Phentolamine Ophthalmic Solution 0.75% for the reversal of pharmacologically-induced mydriasis produced by adrenergic agonist or parasympatholytic agents, or a combination thereof. “The NDA su

MEI Pharma, Inc. a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that it plans to initiate a realignment of its clinical development efforts following the discontinuation of global development outside Japan of its PI3K delta inhibitor, zandelisib. As part of the realignment, the company plans to streamline its organization towards the development of two earlier clinical-stage assets, voruciclib and ME-344. Following completion of the work

China Pharma Holdings, Inc.an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced the Acquisition of Dry Eye Disease Therapeutic Device Project. This device has a patent Epidemiological research shows that the incidence rate of DED is about 25% to 30%, and the incidence rate of people over 65-year-old is 75% in China According to the Research Report on the Market Status of the Glo

JB Chemicals & Pharmaceuticals Ltd (JB Pharma), one of the fastest-growing pharmaceutical companies in India, announced a substantial price decrease of approximately 50% for the critical heart failure drug “Azmarda”.  Azmarda, which contains the patented molecule Saccubutril-Valsartan® is indicated for Heart failure which ails 8 to 12 million people in the country. After the price reduction, Azmarda (Saccubutril-Valsartan®), 50 mg will be available at INR 39.6 per

Novo Nordisk Research Centre China and ATLATL jointly announce the winners of EntreStar program. Hangzhou DNano MetaBio and Modit Medicine stood out among all participants and won the awards.The two winners will be given priority access to one of ATLATL’s nation-wide facilities in China, and a prize of CNY 500K RMB each to pay for the ATLATL facilities and services. They are also entitled to mentoring by relevant experts of Novo Nordisk. There will be no strings attached for the two com

Natus Medical Incorporated a leading provider of medical device solutions focused on the research, diagnosis and treatment of systemic disorders central nervous system and sensory, has entered into a definitive agreement to acquire Micromed Holding SAS ("Micromed Group" or "Micromed"), a global provider of neurophysiology solutions. The transaction is expected to close in early 2023, subject to receipt of appropriate regulatory approvals. The Mic

ADVI Health and Sheridan Capital Partners today announced that Sheridan has taken an ownership stake in ADVI. Together, the companies aim to accelerate, strengthen, and extend ADVI’s position as an established market access, commercialization, and policy firm through the expansion of its solutions and product offerings. Sheridan invested alongside ADVI senior leaders, who retained a meaningful ownership stake in the business and will remain active in the leadership and operations of the

If You Purchased, Paid for, or Provided Reimbursement for the Alzheimer’s Disease Drug Namenda XR or Namenda IR and its AB-rated generic equivalents, between April 14, 2010 through December 31, 2017 (the estimated date that the anticompetitive effects of Generic Defendants’ unlawful conduct ceased), You Could Get Money from a Class Action Settlement.For more detailed information, visit: www.InReNamendaIndirectAntitrustLitigation.com To g